by The biopharma buffer market is estimated to be valued at US$ 3.44 Bn in 2022 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Biopharma buffers are solutions that are used to maintain and stabilize pH levels during biopharmaceutical processes. They play a crucial role in drug formulation, downstream processing, chromatography, cell culture media, and other areas of biopharmaceutical production. Biopharma buffers help maintain an optimal physiological pH that supports cell viability and product quality.
Market key trends:
The growth of the biopharma buffer market is majorly driven by the increasing biopharmaceutical research and development activities. Biopharmaceuticals have revolutionized therapies for diseases such as cancer and other chronic illnesses. Growing prevalence of diseases and demand for innovative therapies have propelled investments in biologics development. Biopharma buffers are extensively used during various stages of biologics production including cell culture, purification, and isolation. Thus, rising focus on development of novel biologics will necessitate increased consumption of biopharma buffers over the forecast period.
Porter’s Analysis
Threat of new entrants: New companies find it difficult to enter the market due to high capital requirement for R&D and manufacturing facilities.
Bargaining power of buyers: Biopharma companies have strong bargaining power due to large order volumes. They can negotiate on price which decreases seller profit margins.
Bargaining power of suppliers: A few major companies supply buffer solutions globally so suppliers have significant influence on pricing.
Threat of new substitutes: No major substitutes exist for buffers in biopharmaceutical manufacturing currently.
Competitive rivalry: Intense competition exists among existing players to gain more market share.
SWOT Analysis
Strength: Established global distribution network and reputed brands of major players. Innovation in buffer solutions to increase process efficiency.
Weakness: High R&D and quality control costs increases product costs. Supply chain disruptions affect just-in-time delivery of buffers.
Opportunity: Rising biologics production increases buffer usage. Emerging countries expanding biopharma output offers new markets.
Threats: Stringent regulations on buffer quality can delay new product approvals. Patent expiries of blockbuster drugs may reduce demand.
Key Takeaways
The Global Biopharma Buffer Market Growth is expected to witness high, exhibiting CAGR of 7.1% over the forecast period, due to increasing demand for biologics. Biologics manufacturing has increased considerably which drives the need for buffers to maintain optimal pH levels during different bioprocessing steps.
Regionally, North America is expected to dominate the biopharma buffer market owing to presence of many biopharma giants and growing biologics production in the region. The Asia Pacific market is anticipated to grow at fastest pace due to rising pharmaceutical output from China, India and other emerging nations.
Key players operating in the biopharma buffer market are Merck KGaA, Thermo Fisher Scientific Inc., Avantor, Inc., Lonza Group Ltd., Bio-Rad Laboratories, Inc., Sartorius AG, Corning Inc., Becton, Dickinson and Company, GE Healthcare, Promega Corporation.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
